Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-637 + docetaxel
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
ABBV-637 + docetaxel is an investigational combination therapy for the treatment of solid tumors, including non-small cell lung cancer (NSCLC). ABBV-637 is an antibody-drug conjugate (ADC) developed by AbbVie that targets the epidermal growth factor receptor (EGFR) on tumor cells and delivers a cytotoxic payload that inhibits Bcl-X protein, promoting apoptosis in cancer cells. Docetaxel is a well-established chemotherapeutic agent classified as a taxane, which disrupts microtubule function and inhibits cell division. The combination aims to leverage targeted delivery of cytotoxic agents via EGFR binding with ABBV-637 while enhancing antitumor activity through the addition of docetaxel’s broad cytotoxic effects. This regimen is currently being evaluated in phase 1 clinical trials for relapsed or refractory solid tumors[1][2][4][6].
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)BCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on ABBV-637 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-637 + docetaxel.